The Interactions of Nintedanib and Oral Anticoagulants—Molecular Mechanisms and Clinical Implications
| Autor: | Daniel Rogowicz, Łukasz Wołowiec, Jan Błażejewski, Alicja Nowaczyk, Grzegorz Grześk, Bartosz Górny, Anita Woźniak-Wiśniewska |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Indoles Lung Neoplasms Antidotes Review 030204 cardiovascular system & hematology Tyrosine-kinase inhibitor lcsh:Chemistry chemistry.chemical_compound Idiopathic pulmonary fibrosis 0302 clinical medicine Risk Factors Antithrombotic nintedanib Drug Interactions lcsh:QH301-705.5 Spectroscopy Anticoagulant General Medicine Blood Coagulation Disorders idiopathic pulmonary fibrosis Computer Science Applications Vascular endothelial growth factor 030220 oncology & carcinogenesis Nintedanib medicine.medical_specialty medicine.drug_class Antineoplastic Agents Hemorrhage direct oral anticoagulants Catalysis Inorganic Chemistry 03 medical and health sciences Pharmacotherapy Internal medicine medicine Humans Physical and Theoretical Chemistry Lung cancer Protein Kinase Inhibitors Molecular Biology business.industry Organic Chemistry Anticoagulants COVID-19 medicine.disease COVID-19 Drug Treatment lcsh:Biology (General) lcsh:QD1-999 chemistry business |
| Zdroj: | International Journal of Molecular Sciences International Journal of Molecular Sciences, Vol 22, Iss 282, p 282 (2021) |
| ISSN: | 1422-0067 |
| DOI: | 10.3390/ijms22010282 |
| Popis: | Nintedanib is a synthetic orally active tyrosine kinase inhibitor, whose main action is to inhibit the receptors of the platelet-derived growth factor, fibroblast growth factor and vascular endothelial growth factor families. The drug also affects other kinases, including Src, Flt-3, LCK, LYN. Nintedanib is used in the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases and lung cancer. The mechanism of action suggests that nintedanib should be considered one of the potential agents for inhibiting and revising the fibrosis process related to COVID-19 infections. Due to the known induction of coagulation pathways during COVID-19 infections, possible interaction between nintedanib and anticoagulant seems to be an extremely important issue. In theory, nintedanib could increase the bleeding risk, thrombosis and lead to thrombocytopenia. The data from clinical trials on the concomitant use of nintedanib and antithrombotic agents is very limited as this patient group was within the standard exclusion criteria. Nintedanib is an important therapeutic option, despite its interaction with anticoagulants. If anticoagulant therapy is necessary, the more effective and safer option is the concomitant administration of DOACs and nintedanib, especially when drug-monitored therapy will be used in patients at high risk of bleeding complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|